Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details an administrative increase in the notional allocation of American Depositary Shares (ADSs) within the US Retirement Savings Plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the notification of ADS allocations at a price of $50.70 per ADS on May 9, 2013, for the following individuals:
- Dr M M Slaoui (Director): 10 ADSs
- Dr K Slaoui (Connected Person): 10 ADSs
- Mr W C Louv (Director): 15 ADSs
- Mrs D P Connelly (Director): 1 ADS
Investor Verification Checklist
- Verify the specific terms of the US Retirement Savings Plan regarding notional ADS allocations.
- Confirm the market price of GSK ADSs on May 9, 2013, to validate the $50.70 transaction price.
- Review the full Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) requirements to ensure compliance context.